» Articles » PMID: 15574513

Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis

Overview
Specialty Nephrology
Date 2004 Dec 3
PMID 15574513
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Connective tissue growth factor (CTGF) is one of the candidate factors that are thought to mediate the downstream profibrotic action of TGF-beta. However, its precise role in renal interstitial fibrogenesis has not yet been clarified. It was demonstrated previously that CTGF was expressed in tubular epithelial cells that had been engulfed by interstitial fibrosis in the remnant kidney of the subtotal nephrectomy (SNx) model. In the present study, co-cultures of tubular epithelial cells (mProx24) and tubulointerstitial fibroblasts (TFB) that mimic the subepithelial mesenchyme in the kidney were used to study the profibrotic effects of TGF-beta1-induced CTGF. In these co-cultures, TGF-beta1 treatment resulted in significantly increased mRNA levels of type I collagen and fibronectin in the TFB. These effects were both direct and indirect, with the latter being mediated by CTGF derived from the co-cultured mProx24. Then TGF-beta1 transgenic mice were subtotally nephrectomized and treated with CTGF antisense oligodeoxynucleotide, and their kidneys were analyzed for fibrosis. Intravenous administration of CTGF antisense oligodeoxynucleotide significantly blocked CTGF expression in the proximal tubular epithelial cells in the remnant kidney of these animals despite the sustained level of TGF-beta1 mRNA. This reduction in CTGF mRNA level paralleled a reduction in mRNA levels of matrix molecules as well as proteinase inhibitors plasminogen activator inhibitor-1 and tissue inhibitor of metalloproteinase-1, suppressing renal interstitial fibrogenesis. In conclusion, tubular CTGF acts as a downstream mediator of the profibrotic effects of TGF-beta1 in the remnant kidney, which is a promising target for antifibrotic drugs designed to treat TGF-beta1-dependent interstitial fibrosis.

Citing Articles

Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease.

Lichner Z, Ding M, Khare T, Dan Q, Benitez R, Praszner M Cells. 2024; 13(11.

PMID: 38891116 PMC: 11172104. DOI: 10.3390/cells13110984.


Mechanisms of norcantharidin against renal tubulointerstitial fibrosis.

Yun Q, Bao Y, Jiang J, Guo Q Pharmacol Rep. 2024; 76(2):263-272.

PMID: 38472637 DOI: 10.1007/s43440-024-00578-5.


Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?.

Teisseire M, Giuliano S, Pages G Biomedicines. 2024; 12(2).

PMID: 38397987 PMC: 10886484. DOI: 10.3390/biomedicines12020385.


Module 4-Deficient CCN2/Connective Tissue Growth Factor Attenuates the Progression of Renal Fibrosis via Suppression of Focal Adhesion Kinase Phosphorylation in Tubular Epithelial Cells.

Amano H, Inoue T, Kusano T, Fukaya D, Kosakai W, Okada H Mol Cell Biol. 2023; 43(10):515-530.

PMID: 37746701 PMC: 10569360. DOI: 10.1080/10985549.2023.2253130.


Is the proximal tubule the focus of tubulointerstitial fibrosis?.

Peng Z, Wang H, Zheng J, Wang J, Xiang Y, Liu C Heliyon. 2023; 9(2):e13508.

PMID: 36846656 PMC: 9950842. DOI: 10.1016/j.heliyon.2023.e13508.